Share this story:

St. Michael's Hospital to Receive VMS+ 3.0 Whole-Heart Analysis System





Toronto, Ontario - TheNewswire - October 16, 2019 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT) (OTC:VPTDF) is pleased to announce that St. Michael's Hospital in Toronto will be receiving the VMS+ 3.0 complete heart analysis system for use in clinical evaluations of cardiac patients.

"We look forward to upgrading to the VMS+ 3.0 into our echo suite for the clinical assessment of our cardiac patients. There are many potential applications for this innovative technology - including assessing ventricular volumes and function after percutaneous valve interventions," commented Dr. Howard Leong-Poi, Head of the Division of Cardiology at St. Michael's Hospital and a Clinician Scientist in the Keenan Research Centre for Biomedical Science.

"We are excited with the response we have received from the recent launch of the VMS+ 3.0 into the Canadian market. Adding another leading hospital to our customer base speaks to the need for a diagnostic tool to assess cardiac chamber volumes and function with accuracy comparable to the gold-standard MRI at a fraction of the cost," notes Dr. George Adams, Ventripoint CEO.

The VMS+ 3.0 system is a cost-effective diagnostic tool for measuring whole heart function utilizing standard 2D ultrasound. Heart disease is a global concern and having a non-invasive system to monitor cardiac patients can enhance the standard of care worldwide. The system provides a seamless integration into the existing echo lab adding less than 5 minutes to a standard 2D echocardiography examination.

The VMS+ 3.0 system is commercially available in Canada and Europe. The system is for investigational use in the United States and pending pre-market 510K clearance by the FDA.

About Ventripoint Diagnostics Ltd.

Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care. For further information please contact:

Dr. George Adams, CEO, Telephone: (519) 803-6937

Email: gadams@ventripoint.com

Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release